Skip to main content
Premium Trial:

Request an Annual Quote

Fabrice Balavoine, Mitchell Nelles, Carol Berry

Quantum Genomics has appointed Fabrice Balavoine as head of research, where he will be responsible for managing partnerships with research labs and converting research results into the development phase.
He will also play a part in the chemical, production and monitoring aspects of products in preclinical development, according to Quantum.
Balavoine, 36, comes to Quantum from drug-discovery company Cerep, where he was head of drug development. He also worked as project leader at the Ecole Nationale Supérieure de Chimie in Paris, and at Harvard Medical School.

XDx, a molecular diagnostics company, has appointed Mitchell Nelles to the position of vice president of research and development and technical operations. In this new and expanded role, Nelles will oversee the growth of XDx’s first service offering, the AlloMap molecular expression test.
Nelles comes to XDx from bioMerieux, where he was vice president of North American research and development.

The molecular cancer profiling company AviaraDx has appointed Carol Berry to the post of vice president of sales.
Berry was formerly responsible for the North American sales and corporate marketing at Ciphergen Biosystems, Dynacare Laboratories, Cerner Corporation, and Roche Biomedical Laboratories.

Filed under

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.